Literature DB >> 8966308

[Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis].

D Correia1, V O Macêdo, E M Carvalho, A Barral, A V Magalhães, M V de Abreu, M L Orge, P Marsden.   

Abstract

With the aim of comparing the therapeutic efficacy, tolerability and toxicity of meglumine antimoniate, aminosidine sulphate and pentamidine isethionate, a field study was conducted on randomized treatment of patients with primary cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis (L(V)b), in Corte de Pedra, BA, from October 1992 up to January 1993. Forty six patients were treated and distributed into three groups, two with 15 and one with 16 subjects. All patients were submitted to clinical examination, histopathological and immunological investigations, as diagnostic criterium. All patients were treated by intramuscular route. Group 1 received pentamidine 4 mg/kg/every 2 days, for 8 applications; Group 2 received aminosidine 20 mg/kg/day, for 20 days, and Group 3 received meglumine 10 mg Sbv/kg/day, for 20 days. Failure of therapy was defined as ulceration of the skin lesion four months after treatment. Such failure occurred in five cases as follows: two cases in patients of group 1 one case in patients of group 2, and two cases in group 3, after the first year of follow up. In the evaluation after three years we reviewed fifteen patients, five in each group; except for one in Group 3, all of them were cured. Statistical significance of the results between the three schedules used was not verified.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8966308     DOI: 10.1590/s0037-86821996000500007

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  14 in total

Review 1.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 2.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

3.  Antihelminthic therapy and antimony in cutaneous leishmaniasis: a randomized, double-blind, placebo-controlled trial in patients co-infected with helminths and Leishmania braziliensis.

Authors:  Tracey Newlove; Luiz H Guimarães; Daniel J Morgan; Leda Alcântara; Marshall J Glesby; Edgar M Carvalho; Paulo R Machado
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

4.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

5.  Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil.

Authors:  Alon Unger; Seth O'Neal; Paulo R L Machado; Luiz H Guimarães; Daniel J Morgan; Albert Schriefer; Olívia Bacellar; Marshall J Glesby; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2009-04       Impact factor: 2.345

6.  The Elderly Respond to Antimony Therapy for Cutaneous Leishmaniasis Similarly to Young Patients but Have Severe Adverse Reactions.

Authors:  Alexsandro Souza do Lago; Maurício Nascimento; Augusto M Carvalho; Neuza Lago; Juliana Silva; José Roberto Queiroz; Lucas P Carvalho; Albert Schriefer; Mary Wilson; Paulo Machado; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2018-03-22       Impact factor: 2.345

7.  Clinical Presentation and Response to Therapy in Children with Cutaneous Leishmaniasis.

Authors:  Carvel Suprien; Paulo N Rocha; Marina Teixeira; Lucas P Carvalho; Luiz H Guimarães; Toby Bonvoisin; Paulo R L Machado; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2020-04       Impact factor: 2.345

Review 8.  Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.

Authors:  Ludovic Reveiz; Ana Nilce Silveira Maia-Elkhoury; Rubén Santiago Nicholls; Gustavo Adolfo Sierra Romero; Zaida E Yadon
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

9.  Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.

Authors:  Dae Hyun Kim; Hye Jin Chung; Joachim Bleys; Reza F Ghohestani
Journal:  PLoS Negl Trop Dis       Date:  2009-02-17

10.  Interventions for American cutaneous and mucocutaneous leishmaniasis.

Authors:  Mariona Pinart; José-Ramón Rueda; Gustavo As Romero; Carlos Eduardo Pinzón-Flórez; Karime Osorio-Arango; Ana Nilce Silveira Maia-Elkhoury; Ludovic Reveiz; Vanessa M Elias; John A Tweed
Journal:  Cochrane Database Syst Rev       Date:  2020-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.